Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

ABSTRACT:

Aims

This retrospective, chart-review study evaluated real-world outcomes post-frontline brigatinib in ALTA-1L.

Methods

Patients from ALTA-1L were followed after brigatinib discontinuation. Outcomes evaluated for second-line (2L) treatment included real-world overall response rate (rwORR), time to treatment discontinuation (rwTTD), and progression-free survival (rwPFS).

Results

Forty of 48 patients received subsequent systemic anticancer therapies; 30 received 2L ALK tyrosine kinase inhibitors (TKIs), mostly lorlatinib (n = 16) or alectinib (n = 8), and 11 received 2L non-ALK TKI therapy (one with alectinib). rwORR was 33% with 2L ALK TKIs and 0% with 2L non-ALK TKI therapy. Median (95% confidence interval [CI]) 2L rwTTD was 34.7 months (4.6-not reached [NR]) for ALK

SUBMITTER: Ahn MJ 

PROVIDER: S-EPMC12758242 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature